Purpose ASCO provisional clinical opinions (PCOs) offer direction to the ASCO membership
after publication or presentation of potential practice-changing data. This PCO addresses …

Background Prostate cancer (PC) is the most common cancer in Western countries. More
than one third of PC patients develop metastatic disease, and the 5-year expected survival …

Purpose: Previous studies show that inhibition of ABCB1 expression overcomes acquired
docetaxel resistance in C4-2B-TaxR cells. In this study, we examined whether …

Activation of the androgen receptor (AR) and its splice variants is linked to advanced
prostate cancer and drives resistance to antiandrogens. The roles of AR and AR variants in …

Aims: Among patients diagnosed with prostate cancer, 10–20% will develop castration-
resistant prostate cancer (CRPC) within 5 years; for 70%, CRPC will metastasize, mostly to …

Background Treatment of metastatic prostate cancer is associated with high personal and
economic burden. Recently, new treatment options for castration-resistant prostate cancer …

Objective: To calculate costs per median overall survival (OS) month in chemotherapy-naïve
patients with metastatic castration-resistant prostate cancer (mCRPC) treated with …

INTRODUCTION Identification of cancer biomarkers that inform clinical decisions and
reduce the use of ineffective therapies is a major goal of precision oncology. An abnormal …

Context Optimal treatment sequencing of abiraterone and enzalutamide in chemotherapy-
naïve metastatic castration-resistant prostate cancer (mCRPC) is challenging. Real-world …

Background The approval of new therapies for metastatic castration-resistant prostate
cancer (mCRPC), including the oral agents abiraterone acetate and enzalutamide, has …